MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway
Liver International · 2025
DOI: 10.1111/liv.70302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Xia Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases, School of Bioscience and Technology, Chengdu Medical College, Chen…. Hauptthemen laut MEDLINE: MicroRNAs, Insulin Receptor Substrate Proteins, Hepatic Stellate Cells, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the research project of Sichuan provincial medical association, Chengdu Medical College Program.
Abstract (Originalsprache)
Background & Aims Hepatic fibrosis is a progressive response to chronic liver injury. A key event in the development of hepatic fibrosis is the activation of hepatic stellate cells (HSCs); emerging research indicates that microRNAs play crucial roles in regulating HSCs activation. However, the specific roles of miR‐126‐3p (miR‐126) and miR‐195‐5p (miR‐195) in liver fibrosis remain inadequately understood.
Methods
We examined the expression of miR‐126 and miR‐195 in activated HSCs, fibrotic liver tissues from animal models, and blood samples from patients with liver disease. The effects on cell proliferation and migration were investigated by MTT, colony formation assay, cell wound healing assay, and Transwell assay. Finally, we evaluated the effect of miR‐126 and miR‐195 on the progression of liver fibrosis in mice.
Results
We revealed that miR‐126 and miR‐195 were markedly downregulated in activated HSCs, fibrotic liver tissues from animal models, and blood samples from patients with liver diseases. Functional experiments demonstrated that the overexpression of miR‐126 and miR‐195 significantly inhibited the proliferation, migration, and fibrotic markers expression in HSCs. Conversely, silencing miR‐126 and miR‐195 produced the opposite effects. Further mechanistic studies showed that miR‐126 and miR‐195 downregulate insulin receptor substrate 1 (IRS1) or phosphoinositide 3‐kinase regulatory subunit 2 (PIK3‐R2), respectively, thereby inhibiting the pro‐fibrotic signalling pathway (IRS1/PI3K) and regulating the functions of HSCs. Importantly, in vivo experiments demonstrated that miR‐126 and miR‐195 markedly alleviated CCL 4 ‐induced hepatic fibrosis in mice.
Conclusions
Our results unravel that miR‐126 and miR‐195 inhibit liver fibrosis by suppressing the IRS/PI3K pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases, School of Bioscience and Technology, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China.
- The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Nanbu People's Hospital, Chengdu, People's Republic of China.
- The 3rd Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital of Chengdu, Chengdu, Sichuan, People's Republic of China.
ORCID-Profile: Liping Ma
Förderung
- National Natural Science Foundation of China
- the research project of Sichuan provincial medical association
- Chengdu Medical College Program
- Technological Innovation R&D Project of Chengdu Science and Technology Bureau
Zitieren
APA
Yuan, X., Zhang, K., Wang, D., Li, J., Lyu, P., Zhao, X., Zhang, K., Li, H., Liu, B., & Ma, L. (2025). MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway. Liver International. https://doi.org/10.1111/liv.70302
Vancouver
Yuan X, Zhang K, Wang D, Li J, Lyu P, Zhao X, et al. MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway. Liver International. 2025. doi:10.1111/liv.70302
BibTeX
@article{Yuan2025,
author = {Yuan, Xia and Zhang, Kun and Wang, Dan and Li, Jie and Lyu, Peng and Zhao, Xuemei and Zhang, Kang and Li, Hongting and Liu, Bo and Ma, Liping},
title = {MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70302}
}
EUVIMED